2. Search Result
Search Result
Results for "

HGC27

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

2

Peptides

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-141891
    M435-1279

    		Wnt E1/E2/E3 Enzyme Cancer
    M435-1279 is a UBE2T inhibitor. M435-1279 inhibits the Wnt/β-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1 .
    M435-1279
  • HY-115974
    GRPR antagonist-1

    		Bombesin Receptor Cancer
    GRPR antagonist-1 is a potent gastrin releasing peptide receptor (GRPR) antagonist, having the cytotoxicity against certain cancer cells (IC50 of 4.97, 4.36 and 3.40 μM in PC3, Pan02 and HGC-27 cells, respectively). GRPR antagonist-1 inhibits HGC-27 cell viability by decreasing the Bcl-2 level and increasing the Bax level, causing apoptosis, with anticancer activity .
    GRPR antagonist-1
  • HY-115975
    GRPR antagonist-2

    		Bombesin Receptor Cancer
    GRPR antagonist-2 is a potent gastrin releasing peptide receptor (GRPR) antagonist, having the cytotoxicity against certain cancer cells (IC50 of 0.77 and 2.5 μM in HGC-27 and Pan02 cells, respectively). Anticancer activity .
    GRPR antagonist-2
  • HY-116038
    Kulinone

    		Others Cancer
    Kulinone has cytotoxic effects against A549, H460 and HGC27 with IC50 values of 6.2, 7.8, 5.6 μg/mL .
    Kulinone
  • HY-170924
    Tubulin polymerization-IN-76

    		Microtubule/Tubulin Apoptosis Mitosis Cancer
    Tubulin polymerization-IN-76 (compound 20b) is a potent and orally active Tubulin polymerization inhibitor. Tubulin polymerization-IN-76 inhibits Tubulin polymerization with an IC50 of 2.505 μM by acting on the colchicine binding site, thereby disrupting intracellular Microtubule networks and interfering with cell mitosis. Tubulin polymerization-IN-76 demonstrates exceptional efficacy against MGC-803 and HGC-27 cells with IC50s of 1.61 and 1.82 nM, respectively. Tubulin polymerization-IN-76 effectively inhibits the colony formation and cell migration activities, and induces G2/M phase cycle arrest and Apoptosis in MGC-803 and HGC-27 cells.Tubulin polymerization-IN-76 shows a broad-spectrum antiproliferative activity .
    Tubulin polymerization-IN-76
  • HY-161301
    PI3K-IN-52

    		PI3K Cancer
    PI3K-IN-52 (compound cis 6g) is a potent inhibitor of PI3K, with IC50 of 0.23 μM in HGC-27 cells. PI3K-IN-52 plays an important role in cancer research[1].
    PI3K-IN-52
  • HY-146743
    Antitumor agent-53

    		Apoptosis Cancer
    Antitumor agent-53 is a potent antitumor agent. Antitumor agent-53 induces cell cycle arrest at the G2/M phase. Antitumor agent-53 inhibits the PI3K/AKT pathway to induce the apoptosis of HGC-27 cells. Antitumor agent-53 has the potential for the research of gastrointestinal tumors .
    Antitumor agent-53
  • HY-168519
    STAT3-IN-36

    		STAT Cancer
    STAT3-IN-36 (compound 11g) is a triple-target inhibitor targeting LRPPRC, STAT3, and CDK1 with anticancer activity. STAT3-IN-36 binds to LRPPRC, STAT3, and CDK1, exerting a stronger anticancer effect than TMF (HY-N6818) or Capecitabine (HY-B0016). STAT3-IN-36 inhibits HGC27 cells with IC50 1.8 μM. .
    STAT3-IN-36
  • HY-168044
    ALKBH1-IN-3

    		AMPK Cancer
    ALKBH1-IN-3 is a potent DNA N6-methyladenine (6mA) demethylase ALKBH1 inhibitor. ALKBH1-IN-3 increases the abundance of 6mA, inhibits cell viability and upregulates the AMP-activated protein kinase (AMPK) signaling pathway in gastric cancer cell lines HGC27 and AGS. ALKBH1-IN-3 is promising for research of cancers, including gastric cancer .
    ALKBH1-IN-3
  • HY-149521
    PI3K-IN-47

    		PI3K Cancer
    PI3K-IN-47 (Compound 27) is a bivalent PI3K inhibitor (IC50: 0.44 nM for PI3Kα, 7.18 nM, 13.92 nM, 22.83 nM for PI3Kβ, PI3Kγ, PI3Kδ). PI3K-IN-47 induces cell cycle arrest in G1 phase, inhibits colony formation and cell migration. PI3K-IN-47 inhibits tumor growth in HGC-27 xenograft mice .
    PI3K-IN-47
  • HY-169412
    MAPK-IN-3

    		MDM-2/p53 CDK Caspase Bcl-2 Family Reactive Oxygen Species p38 MAPK ERK JNK Cancer
    MAPK-IN-3 (Compound 4a) is an anti-proliferative agent that shows particularly strong inhibitory effects on KYSE 30, HCT 116, and HGC 27, with IC50 values of 0.57 μM, 3.27 μM, and 2.28 μM, respectively. MAPK-IN-3 blocks the cell cycle via a p53-dependent mechanism and induces cell apoptosis through a p53-independent mechanism. MAPK-IN-3 downregulates the expression of cell cycle-related proteins like Cyclin D1 and cyclin B1, upregulates pro-apoptotic proteins such as cleaved PARP, cleaved caspase-7, and cleaved caspase-9, and reduces the expression of anti-apoptotic proteins like Bcl-2. Additionally, MAPK-IN-3 increases the intracellular level of ROS in KYSE 30 cells and upregulates the expression of members of the MAPK signaling pathway associated with ROS, such as p-ERK, p-p38 and p-JNK .
    MAPK-IN-3
  • HY-P1727A
    Super-TDU TFA

    		YAP Cancer
    Super-TDU TFA is a specific YAP antagonist targeting YAP-TEADs interaction. Super-TDU TFA suppresses tumor growth in gastric cancer mouse model .
    Super-TDU TFA
  • HY-P1727
    Super-TDU
    4 Publications Verification

    		 YAP Cancer
    Super-TDU is a specific YAP antagonist targeting YAP-TEADs interaction. Super-TDU suppresses tumor growth in gastric cancer mouse model .
    Super-TDU
  • HY-W040150
    (24S,25)-Epoxycholesterol

    		LXR Neurological Disease Inflammation/Immunology Cancer
    24S,25-Epoxycholesterol is an agonist for Liver X Receptor (LXR). 24S,25-Epoxycholesterol exhibits properties in regulating the cholesterol efflux , inhibiting tumor growth against gastric cancer and glioblastoma and inducing apoptosis in BMMC cells .
    (24S,25)-Epoxycholesterol
  • HY-146756
    22-((4-Methoxyphenyl)urea-1-yl)-22-deoxypleuromutilin

    		Bacterial Infection
    22-((4-Methoxyphenyl)urea-1-yl)-22-deoxypleuromutilin (compound 6n) is an antibacterial pleuromutilin derivative against Gram-positive pathogens (GPPs) and Mycoplasma pneumoniae .
    22-((4-Methoxyphenyl)urea-1-yl)-22-deoxypleuromutilin
  • HY-147803
    TrxR-IN-5

    		Reactive Oxygen Species Cancer
    TrxR-IN-5 (compound 4f) is a potent TrxR (thioredoxin reductase) inhibitor, with an IC50 of 0.16 μM. TrxR-IN-5 increases the levels of ROS, thus leading to potent antiproliferative effects. TrxR-IN-5 exhibits prominent anticacer and anti-metastasis effects .
    TrxR-IN-5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: